top of page

3rd Middle East Cystic Fibrosis Conference

MECFA
Oct 16, 2018
0 min read

Comments

Featured Posts

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

A case for improved carrier screening

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

The search for molecular glue in targeted disease control

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p

Recent Posts

Generic form of antibiotic for CF lung infections wins FDA approval

Dual-action therapy for cystic fibrosis shows promise: Study

Chronic health conditions and food insecurity in kids

SoftOx Solutions Advances Cystic Fibrosis Treatment with New Clinical Trial Application

Cystic Fibrosis and Seasonal Respiratory Illnesses: Flu, COVID-19, and RSV

Trikafta benefits seen regardless of prior CFTR modulator use for CF

Blood test in pregnancy accurately diagnoses CF: Study

Personalized nutrition strategy is key in CF, patient interviews show

CF Foundation invests over $7M to support phage therapy development

How Cystic Fibrosis Went From Fatal to Treatable

Archive

Search By Tags

bottom of page